Propanc Biopharma Common Stock Performance
| PPCB Stock | USD 0.19 0.03 13.64% |
The company holds a Beta of -0.43, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Propanc Biopharma, are expected to decrease at a much lower rate. During the bear market, Propanc Biopharma, is likely to outperform the market. At this point, Propanc Biopharma Common has a negative expected return of -2.36%. Please make sure to check Propanc Biopharma,'s potential upside and the relationship between the accumulation distribution and period momentum indicator , to decide if Propanc Biopharma Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Propanc Biopharma Common has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Propanc |
Propanc Biopharma, Relative Risk vs. Return Landscape
If you would invest 111.00 in Propanc Biopharma Common on November 6, 2025 and sell it today you would lose (89.00) from holding Propanc Biopharma Common or give up 80.18% of portfolio value over 90 days. Propanc Biopharma Common is currently does not generate positive expected returns and assumes 7.7731% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of pink sheets are less volatile than Propanc, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Propanc Biopharma, Target Price Odds to finish over Current Price
The tendency of Propanc Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.19 | 90 days | 0.19 | roughly 96.0 |
Based on a normal probability distribution, the odds of Propanc Biopharma, to move above the current price in 90 days from now is roughly 96.0 (This Propanc Biopharma Common probability density function shows the probability of Propanc Pink Sheet to fall within a particular range of prices over 90 days) .
Propanc Biopharma, Price Density |
| Price |
Predictive Modules for Propanc Biopharma,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Propanc Biopharma Common. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Propanc Biopharma,'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Propanc Biopharma, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Propanc Biopharma, is not an exception. The market had few large corrections towards the Propanc Biopharma,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Propanc Biopharma Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Propanc Biopharma, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.48 | |
β | Beta against Dow Jones | -0.43 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | -0.33 |
Propanc Biopharma, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Propanc Biopharma, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Propanc Biopharma Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Propanc Biopharma, generated a negative expected return over the last 90 days | |
| Propanc Biopharma, has high historical volatility and very poor performance | |
| Propanc Biopharma, has some characteristics of a very speculative penny stock | |
| Propanc Biopharma, has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Propanc Biopharma Common currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations. |
Propanc Biopharma, Fundamentals Growth
Propanc Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Propanc Biopharma,, and Propanc Biopharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Propanc Pink Sheet performance.
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 81.65 K | |||
About Propanc Biopharma, Performance
By analyzing Propanc Biopharma,'s fundamental ratios, stakeholders can gain valuable insights into Propanc Biopharma,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Propanc Biopharma, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Propanc Biopharma, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Propanc Biopharma Common performance evaluation
Checking the ongoing alerts about Propanc Biopharma, for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Propanc Biopharma Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Propanc Biopharma, generated a negative expected return over the last 90 days | |
| Propanc Biopharma, has high historical volatility and very poor performance | |
| Propanc Biopharma, has some characteristics of a very speculative penny stock | |
| Propanc Biopharma, has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Propanc Biopharma Common currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations. |
- Analyzing Propanc Biopharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Propanc Biopharma,'s stock is overvalued or undervalued compared to its peers.
- Examining Propanc Biopharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Propanc Biopharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Propanc Biopharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Propanc Biopharma,'s pink sheet. These opinions can provide insight into Propanc Biopharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Propanc Pink Sheet analysis
When running Propanc Biopharma,'s price analysis, check to measure Propanc Biopharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Propanc Biopharma, is operating at the current time. Most of Propanc Biopharma,'s value examination focuses on studying past and present price action to predict the probability of Propanc Biopharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Propanc Biopharma,'s price. Additionally, you may evaluate how the addition of Propanc Biopharma, to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets |